Crinetics prices upsized $500M public offering at $50/share; net proceeds ~$472M

Crinetics Pharmaceuticals, Inc.

Pricing of 10,000,000 shares of common stock at $50.00/share for gross proceeds of $500.0 million.
Net proceeds estimated at approximately $472.0 million (or ~$542.9 million if 1.5M share option exercised).
Underwriters granted 30-day option to purchase up to 1,500,000 additional shares; closing expected October 10, 2024.
Proceeds to fund R&D of clinical-stage candidates, pre-commercialization activities, and general corporate purposes.
Leerink Partners and Morgan Stanley acting as joint bookrunning managers for the offering.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.